Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps) (PrEPSteps)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03512418 |
|
Recruitment Status :
Recruiting
First Posted : April 30, 2018
Last Update Posted : May 13, 2022
|
Sponsor:
Fenway Community Health
Collaborators:
Brigham and Women's Hospital
Gilead Sciences
Information provided by (Responsible Party):
Peter Chai, Fenway Community Health
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study will deploy a novel, personalized, smartphone-based intervention (PrEPSteps) that responds to real-time PrEP adherence and nonadherence detected through the use of a digital pill. The PrEPSteps intervention will be developed and refined through a series of focus groups. Participants will be screened at the Screening Visit, and, if eligible, will then begin using the digital pill system at Study Visit 1 for 2 weeks. At Study Visit 2, participants will undergo randomization to using either PrEPSteps + the digital pill, or the digital pill alone to measure PrEP adherence, for 90 days. Participants will then complete 3 monthly study visits (Study Visits 3-5) where the investigators will assess digital pill adherence, conduct manual pill counts, obtain dried blood spots to confirm adherence, provide substance use disorder counseling, and obtain urine drug screens. At Study Visit 5, the investigators will conduct a semi-structured qualitative interview with participants in the PrEPsteps arm, which will be grounded in the Technology Acceptance Model, in order to understand the user response to PrEPSteps and the digital pill. All participants will complete the final follow-up assessment 3 months after Study Visit 5 (Study Visit 6).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV Infections Substance Use Disorders | Behavioral: PrEPsteps Device: Digital pill Drug: Truvada | Phase 3 |
PrEPSteps is a novel, smartphone-based behavioral intervention that delivers PrEP adherence messages in response to detected PrEP ingestion via an innovative digital pill. PrEPSteps comprises 1) an adaptation of LifeSteps, an evidence-based medication adherence behavioral intervention, with smartphone-delivered booster sessions, 2) messages of contingent reinforcement and corrective feedback, and 3) stimulant use screening, brief assessment, and referral to treatment. In this K23, the investigators will first refine and inform the specification of PrEPSteps with a series of focus groups. The investigators will next test the feasibility, acceptability and potential for an effect of PrEPSteps to boost PrEP adherence in a pilot randomized controlled trial of men who have sex with men (MSM) with stimulant use. Finally, the investigators will conduct qualitative interviews among participants who used PrEPSteps to understand the participant response to living with the intervention.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Pilot randomized controlled trial |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps) |
| Actual Study Start Date : | June 20, 2019 |
| Estimated Primary Completion Date : | May 1, 2023 |
| Estimated Study Completion Date : | May 1, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: PrEPsteps
Participants receive the digital pills with Truvada, plus the PrEPsteps intervention that is programmed at the randomization study visit (Study Visit 2). Participants will use PrEPsteps and the digital pill to measure Truvada adherence for months 1-3.
|
Behavioral: PrEPsteps
Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT). Device: Digital pill The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server. Drug: Truvada Participants receive once daily Truvada as PrEP to prevent HIV. |
|
Active Comparator: Control
Participants receive digital pills with Truvada alone. Participants will use digital pills with Truvada for months 1-3.
|
Device: Digital pill
The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server. Drug: Truvada Participants receive once daily Truvada as PrEP to prevent HIV. |
Primary Outcome Measures :
- Acceptability of the adherence intervention based on qualitative and quantitive questionnaire [ Time Frame: three month study visit ]Acceptability as determined by the mean score of the following questions during study visits (graded on a 1-10 scale): "How satisfied were you with PrEPsteps? How likely are you to recommend PrEPsteps to someone who needs PrEP? How likely are you to recommend PrEPsteps to someone who needs PrEP and uses stimulants?
- Feasibility of the adherence intervention qualitative and quantitive questionnaire [ Time Frame: three month study visit ]Feasibility of PrEPstesps as determined by the mean number of times intervention was accessed by each study participant during the trial
Secondary Outcome Measures :
- Potential of PrEPsteps to improve adherence [ Time Frame: one/two/three month study visits ]Comparison of adherence rate in PrEPsteps group versus control
- Acceptability of the digital pill [ Time Frame: three month visit ]Acceptance of digital pills to monitor PrEP adherence through qualitative interviews
Other Outcome Measures:
- Accuracy of digital pill compared to pill counts and dried blood spot for adherence [ Time Frame: one and three month study visits ]Accuracy of digital pill in measuring PrEP adherence as compared to dried blood spot testing for tenofovir diphosphate
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Gender Based Eligibility: | Yes |
| Gender Eligibility Description: | cisgender men who have sex with men (MSM) |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Cisgender MSM
- Moderate to severe non-alcohol substance use disorder
- Self-reported missed PrEP doses (> or equal to 2 doses in 1 week over past 3 months)
- HIV negative
- On PrEP or initiating PrEP
- Has qualifying laboratory testing: Cr clearance, HBV, liver function tests
- Owns a smartphone with Android or iOS
- Age 18 or older
Exclusion Criteria:
- Non-English speaker
- HIV positive
- History of Crohn's disease or ulcerative colitis
- History of gastric bypass, bowel stricture
- History of GI malignancy or radiation to abdomen
- Unable/unwilling to ingest a digital pill
- Allergy to gelatin, silver or zinc (components of the digital pill)
- Does not qualify for PrEP (abnormal liver function, or Cr Clearance <60)
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03512418
Contacts
| Contact: Peter R Chai, MD, MMS | 617-732-5640 | pchai@bwh.harvard.edu | |
| Contact: Georgia Goodman, BS | 857-301-8820 | ggoodman@fenwayhealth.org |
Locations
| United States, Massachusetts | |
| Fenway Health | Recruiting |
| Boylston, Massachusetts, United States, 02215 | |
| Contact: Peter R Chai, MD, MMS 617-732-5640 pchai@bwh.harvard.edu | |
| Contact: Georgia Goodman, BS 857-301-8820 ggoodman@fenwayhealth.org | |
Sponsors and Collaborators
Fenway Community Health
Brigham and Women's Hospital
Gilead Sciences
Investigators
| Principal Investigator: | Peter R Chai, MD, MMS | Brigham and Women's Hospital |
| Responsible Party: | Peter Chai, Adjunct Faculty, Fenway Community Health |
| ClinicalTrials.gov Identifier: | NCT03512418 |
| Other Study ID Numbers: |
1162312 |
| First Posted: | April 30, 2018 Key Record Dates |
| Last Update Posted: | May 13, 2022 |
| Last Verified: | May 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Device Product Not Approved or Cleared by U.S. FDA: | Yes |
| Product Manufactured in and Exported from the U.S.: | No |
Keywords provided by Peter Chai, Fenway Community Health:
|
HIV Prevention Pre-exposure Prophylaxis Digital Pill Substance Use Disorder |
Additional relevant MeSH terms:
|
Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents Anti-HIV Agents Anti-Retroviral Agents |